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Available online 5 March 2016The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metab-
olism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver
disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are pro-
teins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the
pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In
this review, we focus on the roles of two major hepatokines, fetuin-A and ﬁbroblast growth factor 21 (FGF21),
as well as recently-redeﬁned hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and
leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of
hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular
diseases.
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The prevalence of obesity is increasing worldwide, and is a serious
public health problem in many countries [1]. In particular, abdominal
obesity is well known to be a critical factor in the development and pro-
gression of type 2 diabetes (T2DM), cardiovascular disease (CVD), hy-
pertension, stroke, cancer, sleep apnea, and nonalcoholic fatty liver. This is an open access article underdisease (NAFLD) [2]. Obesity-associated lipolysis induces the release of
free fatty acids into the blood stream [3] and increases subclinical in-
ﬂammation, thereby aggravating insulin resistance in various tissues
[4]. NAFLD, which has been regarded as a hepatic manifestation of met-
abolic syndrome, is a spectrum of chronic liver diseases including sim-
ple steatosis, non-alcoholic steatohepatitis (NASH), and liver cirrhosis
[5]. Evidences suggest that NAFLD is a risk factor for CVD independent
of traditional risk factors [6–8].
Organokines are predominantly produced by and secreted from
their respective tissues (e.g. adipokines from adipose tissue andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Implication of hepatokines in cardiometabolic disorders.
Hepatokine Experimental study Reference Clinical study Reference
Fetuin-A Insulin resistance [25,26]
T2DM [35] T2DM [27–30]
NAFLD [34,37] NAFLD [31]
Inﬂammation [36,38,40] Atherosclerosis [41,42]
Myocardial
infarction
[43,44]
FGF21 Glucose homeostasis [53] T2DM [61,64]
NAFLD [53,55,56] Dyslipidemia [69]
Insulin resistance [55] Carotid IMT [73]
β-cell survival [59] Arterial stiffness [74]
Cardiac hypertrophy [70] Obesity [62]
Insulin resistance [63]
NAFLD [65]
Selenoprotein P Insulin resistance [77,78,83] Insulin resistance [77,79]
Angiogenesis [82] T2DM [77,80]
NAFLD [81]
ANGPTL4 Lipid storage [88] T2DM [91]
Lipid mobilization [88] Carotid artery
sclerosis
[96]
Lipolysis [89,90]
Insulin resistance [90]
NAFLD [91]
Glucose tolerance [91]
Hyperlipidemia [91]
Atherosclerosis [92,93,96]
Inﬂammation [94]
Myocardial infarct [95]
LECT2 Inﬂammation [100,106] Tumorigenesis [102]
Hepatitis [101] Insulin resistance [103]
Tumorigenesis [102] NAFLD [104]
Insulin resistance [103,105]
NAFLD [105]
Abbreviation
FGF21; ﬁbroblast growth factor 21.
ANGPTL4; angiopoietin-like 4.
LECT2; leukocyte cell-derived chemotaxin 2.
T2DM; type 2 diabetes mellitus.
NAFLD; non-alcoholic fatty liver disease.
CVD; cardiovascular disease.
Carotid IMT; carotid intima-media thickness.
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crine, and endocrine activity. Recent studies have shown that the liver
may control whole body energy homeostasis through the regulation of
glucose and lipid metabolism by the secretion of hepatokines, which
are liver-derived proteins [9]. In this review, we summarize recent
ﬁndings about major hepatokines and evaluate the underlying molecu-
larmechanisms that may contribute to understanding the pathogenesis
of cardiometabolic disease as well as the development of novel
treatments.
1.1. Adipose tissue and muscle as endocrine organs
Adipose tissue functions as an endocrine organ by secreting
adipokines as well as storing triglycerides. In adipose tissue, increased
energy storage leads to not only an accumulation of lipids but also in-
ﬂammation, including the inﬁltration and activation of immune cells
[10]. This interaction between adipocytes and immune cells results
in the altered secretion of adipokines, which signiﬁcantly affects the
metabolic state of other tissues including the liver, skeletal muscle,
brain, and vascular system [4,10,11]. Adiponectin is a representative
adipokine that has been shown to be a biomarker of T2DM and CVD
and is also involved in the pathogenesis of these disorders [12]. Other
adipokines such as leptin, resistin, adipocyte fatty acid binding protein
(A-FABP), and retinol-binding protein 4 (RBP4) which is also expressed
in liver [13,14], are now being actively studied as therapeutic targets for
the treatment of T2DM and CVD [4].
Recently, skeletal muscle is also recognized as an endocrine organ,
which was comprehensively reviewed by Pedersen and Febbraio [15].Myokines such as irisin, interleukin-6, interleukin-15, IGF-I, brain-
derived neurotrophic factor (BDNF), and follistatin-related protein 1
are involved in insulin signaling and energy metabolism [16,17]. Fur-
thermore, myokines mediate communication between muscle and adi-
pose tissue, the liver, the brain, and other organs [16,17].
1.2. The liver and hepatokines
In conditions of overnutrition, augmented gluconeogenesis and dys-
lipidemia in the liver induces glucotoxicity and lipotoxicity. Hepatic
lipid accumulation leads to subacute hepatic inﬂammation via nuclear
factor κB (NFκB) activation by releasing proinﬂammatory cytokines
such as interleukin-6 (IL-6), IL-1β, and tumor necrosis factorα (TNFα)
[18], although hepatic triglycerides accumulation does not induce insu-
lin resistance and subclinical inﬂammation under certain conditions
[19–21]. Moreover, hepatic steatosis induces endoplasmic reticulum
(ER) stress, leading to the activation of c-Jun. N-terminal kinase (JNK),
which can inhibit the phosphorylation of insulin receptor substrates-1
(IRS-1) [22]. Therefore, the liver plays a crucial role in the development
of metabolic disorders. Analogous to the action of adipokines and
myokines, the hepatokines produced by the liver regulate whole body
energy homeostasis, and are now considered potential targets for the
treatment of cardiometabolic disorders. Recently, Stefan and Häring
systemically reviewed the role of hepatokines in metabolism [23].
2. Fetuin-A
Fetuin-A (also known asα2-HS-glycoprotein), a 64-kDa phosphory-
lated glycoprotein, is expressed predominantly in the liver [24]. Fetuin-
A was identiﬁed as an endogenous inhibitor of insulin receptor tyrosine
kinase in the liver and skeletalmuscle of rodents [25]. Fetuin-A deﬁcient
mice showed improved insulin sensitivity, suggesting that fetuin-A has
a major role in the regulation of insulin signaling [26]. Moreover, single
nucleotide polymorphisms in human fetuin-A were associated with
T2DM [27,28]. High levels of serum fetuin-A are predictable marker
for the incidence of T2DM after adjusting for risk factors [29,30]. Stefan
et al. demonstrated that serum fetuin-A concentrations are positively
associated with hepatic steatosis measured using magnetic resonance
spectroscopy (MRS) in humans [31]. Pioglitazone, an insulin sensitizing
anti-diabetic drug of the thiazolidinedione class, signiﬁcantly reduces
hepatic fetuin-AmRNA expression inmice [32].We previously reported
that 12 weeks of caloric restriction signiﬁcantly decreases circulating
fetuin-A levels, accompanied by an improvement in visceral fat, glucose
levels, blood pressure, and lipid proﬁles in overweight women with
type 2 diabetes [33].
Fetuin-A plays an important role in palmitate-induced hepatic lipid
accumulation in hepatocytes. Saturated free fatty acids, such as palmi-
tate, contribute to the augmentation of fetuin-A expression through
the activation of the NFκB-dependent pathway [34]. In addition, high
glucose augments transactivation of fetuin-A expression levels by an
ERK1/2-mediated pathway [35]. Fetuin-A stimulates inﬂammatory cy-
tokines in monocytes and adipocytes, and suppresses adiponectin,
which is an adipokine with anti-inﬂammatory properties [36]. Our pre-
vious study showed that palmitate-induced fetuin-A expression stimu-
lates triacylglycerol accumulation in hepatocytes and that adiponectin
inhibits hepatic fetuin-A expression via the adenosin monophosphate-
activated protein kinase (AMPK)-NFκB pathway [37]. A recent study re-
ported that fetuin-A serves as an adaptor protein for saturated fatty acid
and consequently activates Toll-like receptor 4 (TLR4), triggering pro-
duction of proinﬂammatory cytokines [38]. Human clinical data per-
formed by Stefan and Häring also support this ﬁnding [39]. Therefore,
fetuin-A induces an inﬂammatory response and insulin resistance,
which may result in the development of T2DM [40].
However, the association between fetuin-A and CVD appears to be
more complicated. Circulating fetuin-A levels are positively associated
with markers of early atherosclerosis and components of metabolic
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levels of serum fetuin-A can predict the incidence of myocardial infarc-
tion and ischemic stroke independent of other cardiovascular risk pa-
rameters [43]. In particular, a Mendelian randomization approach
showed a causal relationship between serum fetuin-A levels and myo-
cardial infarction risk suggesting that serum fetuin-A levels may be an
effective predictive biomarker for CVD [44]. However, fetuin-A can
bind with Ca2+ and inhibits ectopic calciﬁcation in the vasculature
[45]. In studies of patients with chronic kidney disease (CKD), fetuin-A
concentrations were inversely associated with vascular calciﬁcation,
CV events, and mortality [46]. Ix et al. reported that fetuin-A levels are
inversely associated with coronary artery calciﬁcation among
community-living individuals without CVD [47]. Further research is
needed to explore the exact inﬂuence of fetuin-A in atherosclerosis, vas-
cular calciﬁcation, and CVD according to the diverse underlying clinical
conditions.
3. Fibroblast growth factor 21 (FGF21)
FGF21, a 181-amino acid peptide hormone, acts as a potentmetabol-
ic regulator that is primarily secreted by the liver and to a lesser extent
from adipose tissue and skeletal muscle [48,49]. The expression
of FGF21 is induced in response to various kinds of stress, such as
starvation, cold exposure, excess of nutrient, mitochondrial stress,
and autophagy deﬁciency [49]. FGF21 is regulated by several transcrip-
tion factors including peroxisome proliferator-activated receptor α
(PPARα), PPARγ, retinoic acid rector-β (RAR)-β, and carbohydrate re-
sponsive element-binding protein (ChREBP) [50,51]. FGF21 activity de-
pends on cofactor β-Klotho, which enhances the ability of FGF receptors
(FGFRs) to bind FGF21 [52]. β-Klotho is predominantly expressed in the
liver, white adipose tissue, pancreas, and kidney [51,52]. FGF21 is amet-
abolic hormonewith diverse beneﬁcial effects on energy balance aswell
as glucose and lipid metabolism. FGF21-deﬁcient mice show an impair-
ment of glucose homeostasis and weight gain [53]. Moreover, FGF21-
knockout (KO) mice fed a ketogenic diet demonstrate marked impair-
ment in ketogenesis and develop hepatic steatosis [53]. Conversely,
the administration of FGF21 decreases plasma glucose and triglyceride
levels in both ob/ob and db/db mice without hypoglycemia or weight
gain [54]. FGF21 also improves insulin sensitivity and ameliorates he-
patic steatosis in diet-induced obesity (DIO) mice [55]. The overexpres-
sion of FGF21 suppresses hepatic lipogenesis through the inhibition of
sterol regulatory element-binding protein 1c (SREBP1c) and fatty acid
synthase (FAS) levels in HepG2 cells [56]. FGF21 increases the hepatic
expression of peroxisome proliferator-activated receptor gamma coac-
tivator protein 1α (PGC1α) during the adaptive starvation response
[57]. Moreover, FGF21 modulates PGC1α and induces browning in
white adipose tissue as a defense mechanism against hypothermia
[58]. On the other hand, FGF21 improves the function and survival of
β-cells through activation of the ERK1/2 and Akt pathways, which
may contribute to the favorable effects of FGF21 on glucose homeostasis
in diabetic animals [59]. FGF21 acts as a key mediator of the physiologic
and pharmacologic effects of the PPARγ agonist rosiglitazone [60].
Therefore, FGF21 has the potential to be a promising target for T2DM
because of its effect of reducing blood glucose independently of insulin
[61]. However, paradoxical increases of FGF21 levels are observed in
obesity [62], insulin resistance [63], T2DM [64], and NAFLD [65], despite
the beneﬁcial effects of FGF21 on glucose and lipidmetabolism. Further-
more, in human differentiating preadipocytes, FGF21 has adiponectin-
suppressive and leptin and interleukin-6 release-promoting effects
[66]. Although the exact mechanism is not clear, “FGF21 resistance”
may be provoked by obesity and insulin resistance in rodents and
humans [67]. Fisher et al. reported that DIO mice respond poorly to ex-
ogenous FGF21 and that obesity is an FGF21-resistant state [68]. In a re-
cent randomized clinical trial, treatment with LY2405319, an analog of
FGF21, resulted in signiﬁcant improvements in the dyslipidemia of
obese human subjects with T2DM [69].Recent studies have suggested a possible role of FGF21 in atheroscle-
rosis and CVD. FGF21-deﬁcient mice exhibited impaired cardiac func-
tion and cardiac hypertrophy, which was ameliorated by treatment
with FGF21 [70]. Wu et al. reported that FGF21 ameliorated aortic
plaques and prevented apoptosis in apoE (−/−) mice through attenua-
tion of ER stress and improvement of dyslipidemia [71]. Furthermore,
FGF21 has a protective effect on atherosclerosis through enhancement
of cholesterol efﬂux via the induction of liver X receptor (LXR)α-medi-
ated ATP binding cassette (ABC) A1 and G1 expression in THP-1
macrophage-derived foam cells [72]. Elevated FGF21 concentrations
were associated with carotid intima-media thickness (IMT) in humans,
independent of CVD risk factors [73]. We previously reported that
FGF21 levels are signiﬁcantly associated with brachial-ankle pulse
wave velocity (baPWV) reﬂecting arterial stiffness [74]. Furthermore,
Shen et al. recognized serum FGF21 level as an independent risk factor
of coronary artery disease in multiple logistic regression analysis
(OR = 2.98; 95% CI = 1.01–8.79; P b 0.05) [75].
4. Selenoprotein P
Selenoprotein P, a 42-kDa glycoprotein, is produced in the liver and
plays an important role in the transport of selenium [76]. Misu et al. ﬁrst
identiﬁed selenoprotein P as a hepatokine associated with insulin resis-
tance in humans using serial analysis of gene expression (SAGE) and
DNA chip methods [77]. The administration of selenoprotein P impairs
insulin signaling and glucosemetabolism in both liver and skeletalmus-
cle, whereas selenoprotein P-deﬁcient mice demonstrate improved in-
sulin resistance and glucose tolerance [77]. ER stress induced by
carrageenan increases levels of selenoprotein P mRNA expression and
insulin resistance, whereas AMPK activators ameliorates these changes
in HepG2 cells [78]. Hellwege et al. reported that genetic variants in
selenoprotein P gene were associated with the ﬁrst phase insulin re-
sponse and fasting inulin, supporting a role of selenoprotein P in insulin
resistance [79].Weobserved that circulating selenoprotein P concentra-
tions are elevated in patients with T2DM and prediabetes [80].
Moreover, patients with NAFLD as well as those with visceral obesity
exhibited increased selenoprotein P levels, suggesting that seleno-
protein P is a novel biomarker for NAFLD [81]. On the other hand, we
found that selenoprotein P exhibits an independent associationwith ca-
rotid IMT and high-sensitivity C-reactive protein (hsCRP), an indicator
of systemic subclinical inﬂammation, even after adjusting for other con-
founding factors [80]. Ishikura et al. showed that selenoprotein P in-
hibits vascular endothelial growth factor (VEGF)-stimulated cell
proliferation, tubule formation, and migration in human umbilical vein
endothelial cells (HUVECs) and that wound closure is impaired in
mice overexpressing selenoprotein P [82]. Therefore, the authors
suggested that selenoprotein P is a diabetes-associated hepatokine
that impairs angiogenesis [82]. In our previous study, adiponectin ame-
liorated palmitate-induced insulin resistance by the inhibition of
selenoprotein P in hepatocytes [83].Moreover,Misu et al. demonstrated
that circulating selenoprotein P levels are negatively associated with
adiponectin in patients with T2DM [84], suggesting communication be-
tween adiponectin and selenoprotein P.
5. Angiopoietin-like protein 4 (ANGPTL4)
ANGPTL4, which is also classiﬁed as an adipokine and a myokine,
is predominantly expressed in the liver, adipose tissue, and muscle
[85–87]. ANGPTL4, which plays an important role in lipid storage and
mobilization, is a powerful regulator of lipid metabolism [88]. The ex-
pression of ANGPTL4 can be changed by the nutritional state of
human patients and animal models. ANGPTL4 is under transcriptional
control by fatty acids (FA) and FA-activated PPARs [89]. ANGPTL4 sup-
presses lipoprotein lipase (LPL) activity and leads to lipolysis in adipose
tissue [89]. Gray et al. reported that ANGPTL4 stimulates fasting-
induced intracellular lipolysis by regulation of cAMP signaling in
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abnormal lipolysis such as in insulin resistance [90]. In experimental
in vivo tests, adenovirus-mediated overexpression of ANGPTL4
decreased blood glucose levels and attenuated glucose tolerance to
maintain glucose homeostasis. However, this also led to undesirable hy-
perlipidemia and hepatic steatosis in mice [91]. Serum ANGPTL4 con-
centrations were lower in patients with T2DM than in healthy
controls, supporting the hypothesis that decreased ANGPTL4 might be
a causative factor for T2DM [91].
ANGPTL4 is also expressed in vascular endothelial cells andmay play
an important role in the pathophysiology of atherosclerosis [92].
ANGPTL4 is involved in the regulation of angiogenesis, vascular perme-
ability, oxidative stress, and the inﬂammatory response [92]. Adachi
et al. reported that ANGPTL4 deﬁciency suppresses foam cell formation
and protects against the development and progression of atherosclero-
sis [93]. However, Lichtenstein et al. showed that ANGPTL4 reduces
macrophage activation and foam cell formation, and protects against
saturated fat-induced inﬂammation [94]. In vivo injection of recombi-
nant human ANGPTL4 reduced myocardial infarct size and the extent
of non-reﬂow through the preservation of vascular integrity in mice
and rabbits [95]. Furthermore, transgenic over-expression of ANGPTL4
prevented the development of atherosclerosis via the suppression of
foam cell formation [96]. Plasma ANGPTL4 levels were negatively asso-
ciated with carotid artery sclerosis measured usingmagnetic resonance
imaging (MRI) [96]. Muendlein et al. reported that plasma ANGPTL4
concentrations as well as ANGPTL4 variants can predict future cardio-
vascular events during a mean follow-up period of 3.5 years [97]. How-
ever, Smart-Halajko et al. did not ﬁnd any relationship between plasma
ANGPTL4 levels and coronary heart disease risk in the Northwick Park
Heart Study II [98]. Further research is needed to assess the potential
of ANGPTL4 as a therapeutic target for atherosclerosis and CVD.
6. Leukocyte cell-derived chemotaxin 2 (LECT2)
LECT2 is a 16 kDa secretory protein that acts as an energy-sensing
hepatokine. It was identiﬁed as a novel neutrophil chemotactic protein
predominantly expressed in the adult and fetal liver [99]. Lu et al. re-
ported that the inﬁltration of polymorphonuclear neutrophils andmac-
rophages into the peritoneum after E. coli injection is signiﬁcantly
augmented in LECT2-treatedmice [100]. LECT2, which regulates the ho-
meostasis of natural killer T (NKT) cells, might be involved in the path-
ogenesis of hepatitis [101]. Okabe et al. suggested that serumLECT2may
be a potential biomarker for hepatocellular carcinoma [102]. LECT2may
be a link between obesity and insulin resistance in skeletal muscle. Lan
et al. reported that the administration of recombinant LECT2 impairs in-
sulin signaling through the JNK pathway in myocytes and that LECT2
deﬁciency in mice improves insulin sensitivity in skeletal muscle by ac-
tivation of Akt phosphorylation [103]. The authors also showed a posi-
tive relationship between circulating LECT2 levels, body mass index
(BMI), and insulin resistance in humans [103]. Okumura et al. showed
that circulating LECT2 concentrations are signiﬁcantly increased in pa-
tients with obesity and fatty liver [104]. Recently, we reported that
LECT2 treatment signiﬁcantly increasesmammalian target of rapamycin
(mTOR) phosphorylation, SREBP-1 cleavage, lipid accumulation, and in-
sulin resistance in the HepG2 cells, which are all attenuated by treat-
ment with JNK inhibitor [105]. Furthermore, we showed that LECT2
treatment induces proinﬂammatory cytokines and adhesion molecules
through CD209-mediated JNK phosphorylation in HUVECs [106].
These results suggest that LECT2 may directly mediate the progression
of hepatic steatosis and atherosclerosis.
7. Conclusion
Previous studies have shown that lipid accumulation in the liver is
closely associated with visceral obesity, T2DM, and CVD, conditions
with altered secretory patterns of hepatokines (See Table 1). Therefore,hepatokines have been suggested to be predictive biomarkers of NAFLD,
T2DM, and CVD. Moreover, preclinical studies have shown that
hepatokines have robust effect on hyperglycemia, dyslipidemia, and
body weight in diverse animal models. These ﬁndings have motivated
continuing efforts to investigate the potential of hepatokines as thera-
peutic targets for cardiometabolic diseases. For example, repressing
the expression of hepatic fetuin-A, selenoprotein P, and LECT2 or stim-
ulating the expression of FGF21may contribute to the treatment ofmet-
abolic disorders. Furthermore, the discovery of novel hepatokines may
provide important insights into cardiometabolic diseases such as
T2DM and CVD, leading the way toward promising therapeutics.
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